Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial

Caliway's combination therapy CBL-514 with tirzepatide has been cleared by the U.S. FDA to enter Phase 2 trials targeting abdominal fat reduction in overweight or obese adults. Separately, the pivotal Phase 3 trial SUPREME-01 for large-area abdominal fat reduction has initiated enrollment after U.S. IRB approval.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.